UBS says early flu pick-up could lift 2027 earnings at Reckitt and Haleon

UBS says an early rise in flu incidence could lift 2027 earnings forecasts for Reckitt Benckiser and Haleon. UBS rates Reckitt “buy” with a 7,600p price target, implying 39% upside from its Monday close of 5,484p.

Analysis

The key issue is whether earlier flu activity expands full-season demand or merely pulls cold-and-flu purchases forward. If cases peak earlier but cumulative severity is ordinary, the likely effect is quarterly mix and channel timing—not a durable earnings step-up. A material forecast change needs confirmation in retail/pharmacy sell-through and sustained category volumes, not incidence data alone.

Reckitt’s Mucinex exposure and Haleon’s Theraflu exposure provide direct sensitivity, but competing products from P&G and Kenvue constrain pricing and share gains. An early surge could also prompt retailers to replenish quickly, followed by destocking if the season fades; that creates a second-order risk to subsequent-quarter shipments.

Near term, surveillance data and retailer data are the catalysts. Over 1–3 months, watch whether analysts raise full-season volume assumptions and whether company commentary validates sell-through. The 2027 estimate angle is less compelling without evidence that the demand change persists beyond a seasonal timing shift. UBS’s target is one analyst’s view, not independent confirmation of upside. The thesis weakens if cumulative cases normalize, category sales fail to accelerate, or management commentary points to shipment timing rather than consumer demand.

Key Decisions for Investors

• Do not chase RKT solely on the cited target. Treat the flu signal as an alert; require corroboration from pharmacy/retailer sell-through and upward revisions to full-season estimates before adding exposure.
• For a tactical expression, consider a modest long RKT / long HLN basket rather than a single-name bet, sized as a seasonal catalyst trade. Reassess after the next several weeks of incidence and sales data; avoid assuming an early peak means higher annual sales.
• Monitor weekly respiratory surveillance alongside category sales, retailer inventory commentary, and each company’s guidance. If incidence rises but sell-through or full-season estimates do not, reduce or close the trade.
• No high-conviction pair or options position is warranted from this report alone: the article provides no comparative valuation, consensus revision, or verified sales data to support a relative-value call.